Loading clinical trials...
Loading clinical trials...
The objective of the study is to demonstrate effectiveness of the G6 sensor membrane, in preventing acetaminophen's interference effect on glucose sensing.
The interference effect of the sensor will be evaluated by comparing the bias in the glucose values exhibited from the G6 CGM system after administration of acetaminophen. Bias will be evaluated by comparing CGM values to a laboratory referenceusing venous sample measurements.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
AMCR
Escondido, California, United States
William Sansum Diabetes Center
Santa Barbara, California, United States
Diablo Clinical Research
Walnut Creek, California, United States
Rainier Clinical Research Center Inc
Renton, Washington, United States
Start Date
February 3, 2017
Primary Completion Date
March 4, 2017
Completion Date
March 4, 2017
Last Updated
December 31, 2018
70
ACTUAL participants
Acetaminophen Challenge (G6 CGM)
DEVICE
Lead Sponsor
DexCom, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07480161